XBiotech (XBIT) Net Cash Flow (2014 - 2025)

XBiotech has reported Net Cash Flow for 12 years, with the latest figure at -$23.0 million in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 262.5% year-over-year to -$23.0 million in Q4 2025; TTM through Dec 2025 was -$50.5 million, a 131.28% decrease from a year earlier, with the FY2025 full-year figure at -$50.5 million, down 131.28% from the prior year.
• Net Cash Flow was -$23.0 million for Q4 2025 at XBiotech, down from -$4.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $75.1 million in Q2 2021, with the low at -$76.1 million in Q3 2021.
• Average Net Cash Flow over 5 years is -$5.5 million, with a median of -$5.8 million recorded in 2022.
• The largest YoY upside for Net Cash Flow was 740.67% in 2021 against a maximum downside of 944.23% in 2021.
• Over 5 years, Net Cash Flow stood at -$2.2 million in 2021, then tumbled by 221.12% to -$7.1 million in 2022, then jumped by 49.82% to -$3.5 million in 2023, then slumped by 78.72% to -$6.3 million in 2024, then sank by 262.5% to -$23.0 million in 2025.
• The last three Net Cash Flow figures came in at -$23.0 million (Q4 2025), -$4.4 million (Q3 2025), and -$6.0 million (Q2 2025), per Business Quant data.